Fresenius Medical Care AG (FMS) Stock
FMS has an Alpha Score of 42 out of 100 (weak), computed on Nov 4, 2026 from 3 of 4 sub-scores. 5 members of Congress disclosed 7 trades in FMS since 2017: 3 purchases and 4 sales, most recently Daniel Goldman (sale, Jul 10, 2023). 4 of the hedge funds AlphaScala tracks reported FMS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $35.54M. Its trailing P/E ratio is 11.5 and its net margin 4.8% (key statistics as of Nov 4, 2026).
What is FMS's Alpha Score?
How it works →Alpha Score of 42 reflects weak overall profile with poor momentum, moderate value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Fresenius Medical Care AG (FMS)?
Most recent: Daniel Goldman (sale, Jul 10, 2023); records start Jan 9, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-07-10 | sale | $1k – $15k |
| Dean Phillips D-MN · House | 2021-01-12 | purchase | $1k – $15k |
| Dean Phillips D-MN · House | 2021-01-11 | purchase | $1k – $15k |
| Greg Gianforte R-MT · House | 2019-01-02 | sale | $100k – $250k |
| Josh Gottheimer D-NJ · House | 2018-12-21 | sale | $1k – $15k |
| Tom MacArthur R-NJ · House | 2017-10-25 | sale | $1k – $15k |
| Tom MacArthur R-NJ · House | 2017-01-09 | purchase | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all FMS political trades →Which hedge funds own FMS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.57M | $35.54M | -4% |
| D.E. Shaw David Shaw | 211K | $4.76M | -51% |
| Point72 Steve Cohen | 77K | $1.74M | -85% |
| Citadel Ken Griffin | 38K | $860.3K | -33% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are FMS's key statistics?
Key statistics as of Nov 4, 2026
How does FMS's valuation compare with the Healthcare sector?
| Metric | FMS | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 11.5 | 28.8 | 111 |
| Net margin | 4.83% | 3.66% | 168 |
| Return on equity | 7.21% | 3.80% | 191 |
| Dividend yield (payers) | 3.06% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 8, 2026). P/E excludes loss-making companies.
FMS price chart
Powered by TradingViewWhat does Fresenius Medical Care AG do?
Fresenius Medical Care AG & Co. KGaA ADR represents shares of the global healthcare company specializing in dialysis treatments and related products. The primary function of Fresenius Medical Care is to provide comprehensive care for patients suffering from chronic kidney failure. This includes offering dialysis services and manufacturing essential components such as dialysis machines, dialysis fluids, and related disposables. The company's product and service range is integral to healthcare systems worldwide, impacting hospitals, outpatient dialysis centers, and home care setups. As an American Depository Receipt (ADR), this asset allows investors in the United States stock market to invest in Fresenius Medical Care, which is primarily listed in Germany. This facilitates investment in one of the leading companies in the nephrology sector, providing exposure to the essential healthcare market that continues to expand due to increasing prevalence of chronic diseases globally.